Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment.

about

Prevalence of antiretroviral drug resistance among treatment-naive and treated HIV-infected patients in Venezuela.

P2860

Q57574707-54FC6C6F-A4E6-4C43-9C1E-F45D2B774919

P2860

Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment.

Item

http://www.wikidata.org/entity/Q43750850

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Anti-human immunodeficiency vi ...... tive antiretroviral treatment.

@en

Anti-human immunodeficiency vi ...... tive antiretroviral treatment.

@nl

type

Item

label

Anti-human immunodeficiency vi ...... tive antiretroviral treatment.

@en

Anti-human immunodeficiency vi ...... tive antiretroviral treatment.

@nl

prefLabel

Anti-human immunodeficiency vi ...... tive antiretroviral treatment.

@en

Anti-human immunodeficiency vi ...... tive antiretroviral treatment.

@nl

P1476

Anti-human immunodeficiency vi ...... tive antiretroviral treatment.

@en

P2093

E Priscilla Ouverney

http://www.w3.org/2001/XMLSchema#string

José C Couto-Fernandez

http://www.w3.org/2001/XMLSchema#string

José H Pilotto

http://www.w3.org/2001/XMLSchema#string

Mariza G Morgado

http://www.w3.org/2001/XMLSchema#string

Saada Chequer Fernandez

http://www.w3.org/2001/XMLSchema#string

Valdilea Veloso

http://www.w3.org/2001/XMLSchema#string

Vera Bongertz

http://www.w3.org/2001/XMLSchema#string

P2860

Absence of seroreversion in 80 HAART-treated HIV-1 seropositive patients with at least five-years undetectable plasma HIV-1 viral load.

Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.

Decline in the AIDS and death rates in the EuroSIDA study: an observational study.

Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy.

Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics?

Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART.

Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.

HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy.

Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease.

Vertical HIV-1 transmission: importance of neutralizing antibody titer and specificity.

P304

817-825

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1590/S0074-02762007005000119

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Beatriz Grinsztejn

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5788538

http://www.w3.org/2001/XMLSchema#string

P698

18060317

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment.

about

P2860

P2860

Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921